As of 3:59pm ET
| -0.15 / -2.15%|
The 5 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 8.50, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +24.27% increase from the last price of 6.84.
The current consensus among 6 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.